CASI Pharmaceuticals Inc.

CASIF Healthcare Biotechnology

CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024. In the quarter to December 2025, revenue fell 45.9%, EPS grew 54.4%, free cash flow fell 23,251.7% and total debt rose 6.97%, each against the same quarter a year earlier.

0.10 0.00 0.00%
Market cap
$12.4M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−47.08
Beneish M
−8.73
Dividend safety
n/a
Jun '26 Dec '25 Sep '25 Jun '25 Older periods
Piotroski F-Score
— 3 — —

+8 more TTM periods

ROE
0.00% 271.28% 669.76% 830.72%
ROA
0.00% (121.17%) (112.12%) (113.71%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
0.00% 164.33% 242.48% 385.20%
Average Days of Receivables
0.00 72.11 35.47 62.02
Free Cash Flow per Share
— (3.80) 0.00 0.00
Free Cash Flow
— (70.46) — —
Other line items

Show all line items

Columns are period end dates